Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 7/20 | 0.36 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014454 | 0.88 | RAB9A (0.41) | NPC1RAB9ASMN1; SMN2ATMNPY5R | |
| SCHEMBL1822725 | 0.88 | NOTUM (0.38) | NPC1RAB9ASMN1; SMN2SPRHSD11B1 | |
| SCHEMBL1822634 | 0.81 | SLC6A2 (0.43) | — | |
| SCHEMBL15516297 | 0.77 | TRPM5 (0.38) | TRPM5TRPM4RIPK1FFAR4NPY5R | |
| SCHEMBL1822924 | 0.76 | SLC6A2 (0.44) | — | |
| SCHEMBL1823936 | 0.73 | USP30 (0.42) | — | |
| SCHEMBL15517235 | 0.73 | GRM4 (0.36) | TRPM5TRPM4RIPK1FFAR4NPY5R | |
| SCHEMBL1820929 | 0.73 | SLC6A2 (0.42) | RIPK1 | |
| SCHEMBL22415970 | 0.73 | DRD2 (0.40) | — | |
| SCHEMBL3633982 | 0.70 | GRM2 (0.35) | NPC1RAB9ASMN1; SMN2SPRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155669-B1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-05-04 | — | — | EP | disclosed |
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-08-05 | — | — | US | disclosed |
| EP-2155669-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148799-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | SLC6A2, SLC6A3, SLC18A2 | TRPM5 479/4885TRPM4 545/4885NPC1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.